Inquiry Basket
CAS No.: 796073-70-6
Cat No.: BADC-00022
Purity: ≥98%
4.5 
DM3-SMe serves as an effective ADC cytotoxin with a stable linker, optimized for precise drug delivery in antibody-drug conjugates. It offers strong microtubule inhibition, making it ideal for next-generation ADC cancer therapeutics. Keywords: ADC cytotoxin, microtubule inhibitor, targeted drug conjugate.
Structure of 796073-70-6
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| 5 mg | $729 | In stock | |
| 25 mg | $1573 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
DM3-SMe, also referred to as demethylated maytansine derivative, stands out as a potent cytotoxic compound with diverse applications in biomedical research and therapeutic realms. Here are four key applications of DM3-SMe intricately:
Cancer Research: A pivotal player in the realm of cancer research, DM3-SMe finds extensive utility in the development of antibody-drug conjugates (ADCs) targeted at eradicating cancer cells. It operates by conjugating to an antibody specific to a tumor cell antigen, facilitating the direct delivery of the potent cytotoxic agent to the cancerous cells. This targeted strategy not only minimizes harm to healthy cells but also amplifies therapeutic effectiveness.
Drug Development: Serving as a lead compound in the synthesis of novel chemotherapeutic agents, DM3-SMe empowers researchers in creating derivatives with enhanced potency, selectivity, and reduced side effects. This compound propels the exploration of innovative treatments for diverse cancer types, heralding a new era of drug development and personalized medicine.
Cell Biology Studies: Within cell biology, DM3-SMe assumes a pivotal role in elucidating the impact of microtubule inhibitors on cell division and proliferation dynamics. By disrupting microtubule dynamics, it illuminates the intricacies of cell division mechanisms, unveiling potential therapeutic targets for diseases characterized by unregulated cell proliferation. This profound knowledge serves as a cornerstone for designing cutting-edge cancer therapeutics.
Mechanism of Action Studies: Eminently valuable for decoding the molecular mechanisms underpinning its cytotoxic effects, DM3-SMe is instrumental in unraveling its interactions with cellular components like tubulin and its role in inducing cell death. By comprehending these intricate mechanisms, researchers pave the way for crafting more potent anti-cancer strategies and identifying novel drug targets to combat malignant diseases efficaciously.
What is the mechanism of action for DM3-SMe?
DM3-SMe is a highly potent maytansinoid derivative. It functions as a microtubule inhibitor, disrupting tubulin polymerization and leading to cell cycle arrest and apoptosis. This mechanism is crucial for its cytotoxic activity, making it an effective payload for antibody-drug conjugates (ADCs) designed for targeted therapy.
17/8/2018
Dear BOC Sciences, how does DM3-SMe contribute to ADC efficacy?
As a potent cytotoxic payload, DM3-SMe is a key component of an ADC's therapeutic effect. Once the ADC is internalized by the target cell, DM3-SMe is released, allowing it to exert its potent anti-tubulin activity. This localized delivery minimizes systemic exposure and enhances the therapeutic window.
3/9/2020
We would like to know if DM3-SMe can be conjugated using different methods.
Yes, DM3-SMe is a versatile payload that can be conjugated to antibodies via either a stable thioether or a cleavable disulfide bond. The choice of linker and conjugation chemistry is a critical consideration in ADC design, influencing plasma stability and intracellular payload release for optimal therapeutic outcomes.
12/3/2020
Good afternoon! What is the significance of DM3-SMe in preclinical research?
In preclinical research, DM3-SMe is used as a reference maytansinoid payload due to its well-documented potency and established mechanism of action. It enables researchers to evaluate the efficacy of novel ADC constructs and to compare different conjugation strategies. Its use helps accelerate the development of new targeted therapies.
5/1/2016
Good morning! Could you tell me why DM3-SMe is considered a second-generation ADC payload?
DM3-SMe is classified as a second-generation ADC payload due to its optimized structure, which confers high potency. It represents an advancement over earlier maytansinoid derivatives, offering improved stability and a more favorable profile for conjugation. Its application in clinical and preclinical studies highlights its status as a key component in modern ADC design.
6/12/2021
— Dr. Jason Carter, Senior Scientist (USA)
DM3-SMe from BOC Sciences consistently provided high purity, enabling reliable ADC payload attachment.
12/3/2020
— Dr. Olivia Bennett, ADC Chemist (UK)
Batch-to-batch reproducibility of DM3-SMe helped maintain accuracy across long-term experiments.
6/12/2021
— Dr. Markus Klein, Medicinal Chemist (Germany)
Fast shipping and QC transparency for DM3-SMe improved laboratory workflow efficiency.
5/1/2016
— Dr. Emily Hughes, Biochemist (Canada)
Reliable DM3-SMe allowed uninterrupted multi-step ADC conjugation procedures.
17/8/2018
— Dr. William Adams, Lead Scientist (USA)
Technical guidance on DM3-SMe handling enhanced reproducibility and reduced errors.
— Dr. Sophie Morel, Research Scientist (France)
Consistent DM3-SMe quality combined with professional support enabled accelerated experimental timelines.
3/9/2020
DM3-SMe
Required fields are marked with *
DM3-SMe
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
